KEGG   DRUG: Sofosbuvir and velpatasvir
Entry
D10827            Mixture   Drug                                   
Name
Sofosbuvir and velpatasvir;
Epclusa (TN)
Product
EPCLUSA (Gilead Sciences)
  Generic
SOFOSBUVIR AND VELPATASVIR (Asegua Therapeutics LLC)
Component
Sofosbuvir [DR:D10366], Velpatasvir [DR:D10806]
Class
Antiviral
 DG03198  Anti-HCV agent
Metabolizing enzyme substrate
 DG02919  CYP2B6 substrate
 DG02918  CYP2C8 substrate
 DG01633  CYP3A/CYP3A4 substrate
  DG02913  CYP3A4 substrate
Transporter substrate
 DG01665  ABCB1 substrate
 DG01913  ABCG2 substrate
Transporter inhibitor
 DG01622  ABCB1 inhibitor
 DG02862  ABCG2 inhibitor
 DG02865  SLCO1B1 inhibitor
 DG02907  SLCO1B3 inhibitor
Remark
Therapeutic category: 6250
ATC code: J05AP55
Product: D10827<JP/US>
Efficacy
Antiviral
  Disease
Hepatitis C virus infection [DS:H00413]
Comment
Sofosbuvir and Velpatasvir are substrates of BCRP and P-gp.
Velpatasvir is metabolized by CYP2B6, CYP2C8 and CYP3A4, and it is an inhibitor of the following transporters: P-gp, BCRP, OATP1B1 and OATP1B3.
Target
HCV NS5A [KO:K22275]
HCV NS5B [KO:K22472]
Metabolism
Enzyme: CYP2B6 [HSA:1555], CYP2C8 [HSA:1558], CYP3A4 [HSA:1576]
Transporter: ABCB1 [HSA:5243], ABCG2 [HSA:9429]
Interaction
Transporter inhibition: ABCB1 [HSA:5243], ABCG2 [HSA:9429], SLCO1B1 [HSA:10599], SLCO1B3 [HSA:28234]
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 J ANTIINFECTIVES FOR SYSTEMIC USE
  J05 ANTIVIRALS FOR SYSTEMIC USE
   J05A DIRECT ACTING ANTIVIRALS
    J05AP Antivirals for treatment of HCV infections
     J05AP55 Sofosbuvir and velpatasvir
      D10827  Sofosbuvir and velpatasvir <JP/US>
USP drug classification [BR:br08302]
 Antivirals
  Anti-hepatitis C (HCV) Agents
   Sofosbuvir/ Velpatasvir
    D10827  Sofosbuvir and velpatasvir
Therapeutic category of drugs in Japan [BR:br08301]
 6  Agents against pathologic organisms and parasites
  62  Chemotherapeutics
   625  Antivirals
    6250  Antivirals
     D10827  Sofosbuvir and velpatasvir
Drug groups [BR:br08330]
 Antiviral
  DG03198  Anti-HCV agent
   D10827  Sofosbuvir and velpatasvir
 Metabolizing enzyme substrate
  DG02919  CYP2B6 substrate
   D10827  Sofosbuvir and velpatasvir
  DG02918  CYP2C8 substrate
   D10827  Sofosbuvir and velpatasvir
  DG01633  CYP3A/CYP3A4 substrate
   DG02913  CYP3A4 substrate
    D10827  Sofosbuvir and velpatasvir
 Transporter substrate
  DG01665  ABCB1 substrate
   D10827  Sofosbuvir and velpatasvir
  DG01913  ABCG2 substrate
   D10827  Sofosbuvir and velpatasvir
 Transporter inhibitor
  DG01622  ABCB1 inhibitor
   D10827  Sofosbuvir and velpatasvir
  DG02862  ABCG2 inhibitor
   D10827  Sofosbuvir and velpatasvir
  DG02865  SLCO1B1 inhibitor
   D10827  Sofosbuvir and velpatasvir
  DG02907  SLCO1B3 inhibitor
   D10827  Sofosbuvir and velpatasvir
Drug classes [BR:br08332]
 Antiviral
  DG03198  Anti-HCV agent
   D10827  Sofosbuvir and velpatasvir
Antimicrobials [BR:br08307]
 Antivirals
  Genome replication inhibitor
   HCV NS5A/NS5B inhibitor
    D10827  Sofosbuvir and velpatasvir <JP/US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D10827
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D10827
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D10827
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D10827
Drug metabolizing enzymes and transporters [br08309.html]
 Drug metabolizing enzymes
  D10827
 Drug transporters
  D10827
Other DBs
PubChem: 319902627
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system